Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FULC NASDAQ:OCGN NASDAQ:RANI NASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFULCFulcrum Therapeutics$3.69+9.5%$7.02$2.83▼$15.74$224.55M2.932.67 million shs3.95 million shsOCGNOcugen$1.28-6.6%$1.60$0.90▼$2.73$463.77M2.195.52 million shs5.26 million shsRANIRani Therapeutics$0.83-7.7%$0.92$0.39▼$3.87$111.32M0.741.20 million shs845,325 shsSTTKShattuck Labs$4.58-4.6%$6.54$0.71▼$8.33$368.07M1.08572,970 shs1.12 million shsThe Rise of the RobotsRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and industrial operations. This report explores the rise of “Physical AI,” highlights four key ways investors can gain exposure to the robotics revolution, and profiles seven leading companies positioned to benefit from the growing demand for intelligent automation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFULCFulcrum Therapeutics+4.66%-50.59%-51.99%-58.75%-52.06%OCGNOcugen+5.38%-2.84%-8.05%-14.91%+54.42%RANIRani Therapeutics+2.69%-5.56%+1.66%-30.88%+60.49%STTKShattuck Labs+1.05%-19.60%-26.61%-19.87%+313.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFULCFulcrum Therapeutics$3.69+9.5%$7.02$2.83▼$15.74$224.55M2.932.67 million shs3.95 million shsOCGNOcugen$1.28-6.6%$1.60$0.90▼$2.73$463.77M2.195.52 million shs5.26 million shsRANIRani Therapeutics$0.83-7.7%$0.92$0.39▼$3.87$111.32M0.741.20 million shs845,325 shsSTTKShattuck Labs$4.58-4.6%$6.54$0.71▼$8.33$368.07M1.08572,970 shs1.12 million shsThe Rise of the RobotsRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and industrial operations. This report explores the rise of “Physical AI,” highlights four key ways investors can gain exposure to the robotics revolution, and profiles seven leading companies positioned to benefit from the growing demand for intelligent automation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFULCFulcrum Therapeutics+4.66%-50.59%-51.99%-58.75%-52.06%OCGNOcugen+5.38%-2.84%-8.05%-14.91%+54.42%RANIRani Therapeutics+2.69%-5.56%+1.66%-30.88%+60.49%STTKShattuck Labs+1.05%-19.60%-26.61%-19.87%+313.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFULCFulcrum Therapeutics 1.75Reduce$8.20122.22% UpsideOCGNOcugen 2.60Moderate Buy$9.50642.19% UpsideRANIRani Therapeutics 2.60Moderate Buy$8.75954.85% UpsideSTTKShattuck Labs 2.80Moderate Buy$12.14165.13% UpsideCurrent Analyst Ratings BreakdownLatest RANI, OCGN, FULC, and STTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2026STTKShattuck Labs Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform$7.006/5/2026STTKShattuck Labs CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$7.006/3/2026FULCFulcrum Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Underweight6/2/2026FULCFulcrum Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeUnderperform ➝ Underweight6/2/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/2/2026STTKShattuck Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/2/2026FULCFulcrum Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.006/2/2026FULCFulcrum Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$4.006/2/2026FULCFulcrum Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$3.006/2/2026FULCFulcrum Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/2/2026FULCFulcrum Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$4.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFULCFulcrum Therapeutics$80M3.07N/AN/A$6.45 per share0.57OCGNOcugen$4.41M98.26N/AN/A($0.04) per share-32.00RANIRani Therapeutics$1.63M63.04N/AN/A$0.34 per share2.44STTKShattuck Labs$1M351.19N/AN/A$1.30 per share3.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFULCFulcrum Therapeutics-$74.88M-$1.15N/AN/AN/AN/A-27.80%-26.32%8/4/2026 (Estimated)OCGNOcugen-$67.85M-$0.24N/AN/AN/A-1,192.18%-127,987.80%-135.48%7/30/2026 (Estimated)RANIRani Therapeutics-$29.67M-$0.41N/AN/AN/AN/A-206.46%-83.95%8/6/2026 (Estimated)STTKShattuck Labs-$48.81M-$0.63N/AN/AN/AN/A-60.73%-55.75%8/13/2026 (Estimated)Latest RANI, OCGN, FULC, and STTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026RANIRani Therapeutics-$0.06-$0.04+$0.02-$0.04$1.13 million$1.71 million5/7/2026Q1 2026STTKShattuck Labs-$0.14-$0.13+$0.01-$0.13N/AN/A5/5/2026Q1 2026OCGNOcugen-$0.05-$0.06-$0.01-$0.06$0.42 million$1.53 million4/27/2026Q1 2026FULCFulcrum Therapeutics-$0.31-$0.25+$0.06-$0.25N/AN/A3/26/2026Q4 2025RANIRani Therapeutics-$0.03-$0.07-$0.04-$0.07$5.00 million$1.46 million3/5/2026Q4 2025STTKShattuck Labs-$0.12-$0.12N/A-$0.12$0.17 million($1.00) millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFULCFulcrum TherapeuticsN/A34.3334.33OCGNOcugen4.171.861.86RANIRani TherapeuticsN/A3.403.40STTKShattuck LabsN/A22.0722.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFULCFulcrum Therapeutics89.83%OCGNOcugen10.27%RANIRani Therapeutics30.19%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipFULCFulcrum Therapeutics7.00%OCGNOcugen3.95%RANIRani Therapeutics26.73%STTKShattuck Labs8.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFULCFulcrum Therapeutics10066.63 million61.97 millionOptionableOCGNOcugen80338.52 million325.15 millionOptionableRANIRani Therapeutics110123.88 million90.77 millionOptionableSTTKShattuck Labs10076.68 million69.94 millionOptionableRANI, OCGN, FULC, and STTK HeadlinesRecent News About These CompaniesShattuck Labs to Present Phase 1 Clinical Data for SL-325 and Pipeline Update on June 8, 20264 hours ago | quiverquant.comQShattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 84 hours ago | markets.businessinsider.comShattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 84 hours ago | globenewswire.comShattuck Labs: Priced As If Risk Was Not A Part Of The EquationMay 22, 2026 | seekingalpha.comShattuck Labs (NASDAQ:STTK) Insider Sells $14,244.32 in StockMay 15, 2026 | insidertrades.comWe're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn RateMay 11, 2026 | finance.yahoo.comShattuck Labs (NASDAQ:STTK) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSMay 8, 2026 | marketbeat.comWedbush Forecasts Strong Price Appreciation for Shattuck Labs (NASDAQ:STTK) StockMay 8, 2026 | marketbeat.comShattuck Labs, Inc.: Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026 | finanznachrichten.deShattuck Labs Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026 | globenewswire.comCantor Fitzgerald Initiates Coverage of Shattuck Labs (STTK)May 1, 2026 | insidermonkey.comShattuck Labs (STTK) price target increased by 24.00% to 12.65April 29, 2026 | msn.comCantor Fitzgerald initiates coverage of Shattuck Labs (STTK) with overweight recommendationApril 28, 2026 | msn.comShattuck Labs: Surviving In An AI World Is Going To Be ToughMarch 27, 2026 | seekingalpha.comShattuck Labs (STTK) price target increased by 37.93% to 10.20March 27, 2026 | msn.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Shattuck Labs (STTK), Oruka Therapeutics (ORKA) and Option Care Health (OPCH)March 14, 2026 | theglobeandmail.comShattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business ...March 5, 2026 | caledonianrecord.comCShattuck Labs Advances SL-325 Clinical Trials, Reports Financial Results for Q4 and Full Year 2025March 5, 2026 | quiverquant.comQShattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business HighlightsMarch 5, 2026 | globenewswire.comShattuck Labs Announces Participation in Upcoming March Investor ConferencesFebruary 25, 2026 | globenewswire.comShattuck Labs Sets Earlier Date for 2026 Annual MeetingFebruary 21, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026IonQ Just Posted a Breakout Quarter—But 1 Problem RemainsBy Nathan Reiff | May 7, 2026Aggressive Insider Buying Signals Opportunity in 3 Risky StocksBy Thomas Hughes | June 2, 2026AI's Power Crunch Is Putting Uranium Energy Back on Investors' WatchlistsBy Jessica Mitacek | June 3, 2026RANI, OCGN, FULC, and STTK Company DescriptionsFulcrum Therapeutics NASDAQ:FULC$3.69 +0.32 (+9.50%) Closing price 04:00 PM EasternExtended Trading$3.60 -0.09 (-2.57%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Ocugen NASDAQ:OCGN$1.28 -0.09 (-6.57%) Closing price 04:00 PM EasternExtended Trading$1.34 +0.06 (+4.69%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.Rani Therapeutics NASDAQ:RANI$0.83 -0.07 (-7.69%) Closing price 04:00 PM EasternExtended Trading$0.86 +0.03 (+3.19%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.Shattuck Labs NASDAQ:STTK$4.58 -0.22 (-4.58%) Closing price 04:00 PM EasternExtended Trading$4.95 +0.37 (+8.06%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
